help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kearney, T.
Right arrow Articles by Johnston, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kearney, T.
Right arrow Articles by Johnston, D. G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHOLESTEROL
The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 8 3900-3906
Copyright © 2001 by The Endocrine Society


Other Original Articles

Hypopituitarsim Is Associated with Triglyceride Enrichment of Very Low-Density Lipoprotein

Tara Kearney, Carmen Navas de Gallegos, Alexandra Chrisoulidou, Robert Gray, Peter Bannister, Soundararajan Venkatesan and Desmond G. Johnston

Department of Metabolic Medicine, St. Mary’s Hospital, Imperial College of Science, Technology, and Medicine, Paddington, London, United Kingdom

Address all correspondence and requests for reprints to: Tara Kearney, M.D., Department of Metabolic Medicine, St. Mary’s Hospital, Imperial College of Science, Technology, and Medicine, Paddington, London, United Kingdom. E-mail: t.kearney{at}ic.ac.uk

Abstract

The dyslipidemia associated with hypopituitarism may contribute to increased vascular mortality. The atherogenic potential of lipoproteins is determined not only by concentration but also by their composition. We therefore studied very low-density lipoprotein composition and apolipoprotein B kinetics in 16 hypopituitary subjects and 16 controls. Hypopituitarism was associated with reduced high-density lipoprotein cholesterol (0.98[0.82–1.18] vs. 1.35[1.15–1.41] mmol/liter, P < 0.001) and increased triglyceride concentrations (1.64[1.09–2.77] vs. 1.12[0.66–1.67] mmol/liter, P = 0.01). Total (P = 0.76) and low-density lipoprotein cholesterol (P = 0.56) concentrations were similar. Very low-density lipoprotein- triglyceride was significantly increased (1.48[1.02–2.55] vs. 0.9[0.31–2.30] mmol/liter, P = 0.004), but very low-density lipoprotein cholesterol levels were similar (P = 0.93). The molar ratios of very low-density lipoprotein-triglyceride:apolipoprotein B (6193[4283–9566] vs. 3599[3188–6854], P = 0.005) and very low-density lipoprotein-triglyceride:cholesterol (2.8[1.98–3.78] vs. 1.6[1.44–2.80], P < 0.003) were significantly increased; very low-density lipoprotein-cholesterol:apolipoprotein B molar ratios (P = 0.93) were similar. Very low-density lipoprotein apolipoprotein B fractional synthetic rate (a measure of apolipoprotein B catabolism, P = 0.42) and pool size (P = 0.63) were similar. The very low-density lipoprotein apolipoprotein B absolute synthetic rate (a measure of apolipoprotein B synthesis) tended to be higher in hypopituitarism (17.7[2.91–19.50] vs. 26.6[19.64–28.05] mg/kg per day, P = 0.24) but failed to reach statistical significance. The absolute synthetic rate, and hence very low-density lipoprotein production, correlated with very low-density lipoprotein triglyceride:apolipoprotein B ratio (P = 0.02, Rs = 0.63), suggesting that triglyceride enrichment of very low-density lipoprotein is important in the mechanism underlying very low-density lipoprotein overproduction in hypopituitarism. Because triglyceride-enriched lipoproteins are proatherogenic, this may contribute to the vascular mortality observed in hypopituitarism. The reasons for these observations are unknown; GH deficiency or routine endocrine replacement may be important.




This article has been cited by other articles:


Home page
J. Lipid Res.Home page
R. Ramakrishnan
Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments
J. Lipid Res., December 1, 2006; 47(12): 2738 - 2753.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
E. R Christ, M. H Cummings, M. Stolinski, N. Jackson, P. J Lumb, A. S Wierzbicki, P. H Sonksen, D. L Russell-Jones, and A M. Umpleby
Low-density lipoprotein apolipoprotein B100 turnover in hypopituitary patients with GH deficiency: a stable isotope study.
Eur. J. Endocrinol., March 1, 2006; 154(3): 459 - 466.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. R. Christ, M. H. Cummings, N. Jackson, M. Stolinski, P. J. Lumb, A. S. Wierzbicki, P. H. Sonksen, D. L. Russell-Jones, and A. M. Umpleby
Effects of Growth Hormone (GH) Replacement Therapy on Low-Density Lipoprotein Apolipoprotein B100 Kinetics in Adult Patients with GH Deficiency: A Stable Isotope Study
J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1801 - 1807.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Srinivasan, G. D. Ogle, S. P. Garnett, J. N. Briody, J. W. Lee, and C. T. Cowell
Features of the Metabolic Syndrome after Childhood Craniopharyngioma
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 81 - 86.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. B. Twickler, M. J. M. Cramer, G. M. Dallinga-Thie, M. J. Chapman, D. W. Erkelens, and H. P. F. Koppeschaar
Adult-Onset Growth Hormone Deficiency: Relation of Postprandial Dyslipidemia to Premature Atherosclerosis
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2479 - 2488.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. B. Twickler, H. C. M. T. Prinsen, W. R. de Vries, H. P. F. Koppeschaar, and M. G. M. de Sain-van der Velden
Analysis of the Separate Secretion of Very Low-Density Lipoprotein (VLDL)-1 and VLDL-2 by the Liver Will Be a Principal Factor in Resolving the Proatherogenic Lipoprotein Profile in Hypopituitarism
J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1907 - 1907.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2001 by The Endocrine Society